ASCO GU 2017: Active Surveillance Patient Perspective Question and Answer Panel - Session Highlights

Orlando, Florida USA ( Howard Wolinsky is a freelance journalist in the Chicago, Illinois, area and an adjunct lecturer for graduate health and science writing at Northwestern University’s Medill School of Journalism. Since his diagnosis with prostate cancer (PC) in 2010, Mr. Wolinsky has written a series of articles in MedPage Today that document his experiences on active surveillance (AS). He is the first patient ever invited to become a panelist at the genitourinary symposium.

ASCO GU 2017: Some Patients Experience Long-Term Tumor Control Even After Stopping Immunotherapy Early

ALEXANDRIA, Va. – ( Early findings from a new study appear to challenge the current standard practice for immune checkpoint inhibitor therapy – continuing treatment until cancer worsens. Among patients with advanced kidney cancer who stopped PD1/PD-L1 immunotherapy early due to side effects, 42% had a durable response, meaning they were able to remain off additional systemic therapy for 6 months or more. More broadly, this insight may help alleviate some patients’ concerns about the impact of discontinuing immunotherapy. The study will be presented at the upcoming 2017 Genitourinary Cancers Symposium in Orlando.

ASCO GU 2017: Blood Test Uncovers Potential New Treatment Targets in Advanced Prostate Cancer

ALEXANDRIA, Va. – ( Analysis of free-floating cancer DNA from blood samples has yielded leads for new prostate cancer treatment targets. Using a commercially available “liquid biopsy” test in patients with advanced prostate cancer, researchers found a number of genetic changes in cell-free, circulating tumor DNA (ctDNA). Cell-free ctDNA is tumor DNA that is circulating freely in the patient’s bloodstream. The study will be presented at the upcoming 2017 Genitourinary Cancers Symposium in Orlando.

ASCO GU 2017: In Advanced Kidney Cancer, Antibiotic Use Lowers Efficacy of Immunotherapy

ALEXANDRIA, Va. – A new retrospective analysis suggests that immunotherapy may be less effective in patients who receive antibiotics less than a month before starting treatment. In the study, cancer worsened more quickly in such patients than in those who did not receive antibiotics (median progression-free survival 2.3 months vs. 8.1 months). The study will be presented at the upcoming 2017 Genitourinary Cancers Symposium in Orlando.

2017 Genitourinary Cancers Symposium Press Program to Feature Research Advances in Prostate, Urothelial, Kidney Cancers

Co-sponsors of the 2017 Genitourinary Cancers Symposium announced today three abstracts to be highlighted in the meeting's official Press Program. Researchers will present the findings of these studies in an embargoed presscast for reporters, taking place Monday, February 13, 2017, from 12:00 noon - 1:30 PM (ET).


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.